Expert Interview
A second look: Discussing Silence Therapeutics' divesiran and Protagonist's rusfertide as potential therapies in Polycythemia Vera
Ticker(s): SLN, PTGXInstitution: Moffitt Cancer Center
- Hematologist/Oncologist, and Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology.
- Manages 200-250 patients with myelofibrosis.
- Clinical and research efforts focused on myeloproliferative neoplasms (MPNs), MDS/MPN overlap syndromes and systemic mastocytosis (SM) where he is dedicated to developing novel, disease-modifying therapies for these rare diseases; PI of numerous clinical trials and an active member of the MPN-Research Consortium.
How are you currently treating PV?
Added By: wilson_adminWhat are your opinions on the clinical data presented on divesiran?
Added By: wilson_adminWhat are your opinions on the clinical data presented on rusfertide?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
